Emmanuelle Charpentier Nobel Lecture: CRISPR-Cas9 Genome Editing

Added:

Ethical and Safety Limits of CRISPR-Cas9: Off-Target Risks and Germline Alterations

While CRISPR-Cas9 is celebrated for its revolutionary precision and simplicity, a critical counterpoint focuses on its significant technical limitations and profound ethical dilemmas. Technically, the system is prone to 'off-target effects,' where DNA is cut at unintended genomic sites, potentially causing cancerous mutations or genomic instability. Additionally, double-strand breaks induced by Cas9 can trigger complex cellular toxicity or unwanted deletions. Ethically, the application of CRISPR to human germline editing (making heritable changes) faces intense global criticism. Opponents argue that germline modification risks introducing permanent, unforeseen genetic errors into the human gene pool, exacerbating social inequalities, and paving the way for eugenics. Furthermore, the ecological risks of using CRISPR-based 'gene drives' to alter entire wild populations raise severe biodiversity and biosecurity concerns, prompting many scientists and ethicists to advocate for strict regulatory moratoriums rather than unfettered deployment.

The Central Dogma of Molecular Biology: Understanding how genetic information flows from DNA to RNA to protein.
Basic DNA and RNA structure, including complementary base pairing (A-T, C-G, A-U), which is fundamental to how guide RNAs target specific genomic sequences.
The concept of bacterial adaptive immunity, specifically how bacteria naturally defend themselves against viral invaders (bacteriophages).
An overview of legacy genetic engineering technologies (like restriction enzymes, zinc finger nucleases, and TALENs) to provide context for CRISPR's revolutionary efficiency.
Advanced gene-editing modalities evolved from CRISPR-Cas9, such as base editors, prime editors, and CRISPR activation/interference (CRISPRa/CRISPRi).
The biological delivery vehicles necessary to introduce CRISPR machinery into living cells, including lipid nanoparticles (LNPs) and adeno-associated viruses (AAVs).
Real-world clinical applications and ongoing trials, such as ex vivo therapies for sickle cell disease and beta-thalassemia, as well as in vivo therapies for hereditary diseases.
The ethical, ecological, and regulatory challenges of gene editing, including the debate surrounding human germline editing and the deployment of gene drives in nature.
127.2K views2.7Klikes26:54@NobelPrizeOriginal Release: 2020-12-08

CRISPR-Cas9 is a revolutionary genome editing technology that enables precise modification of DNA sequences. It consists of a Cas9 protein (which acts like molecular scissors to cut DNA) and a guide RNA (which directs Cas9 to a specific location in the genome). The system was originally discovered as part of bacteria's natural immune defense mechanism against viral infections, where bacteria use CRISPR arrays to store genetic memories of past infections and Cas proteins to destroy invading viral DNA. Scientists adapted this system for genome editing by programming the guide RNA to target any desired DNA sequence, allowing researchers to delete, insert, or modify genes with unprecedented precision and efficiency. This technology has transformed genetic research across diverse organisms including human cells, plants, and animals, enabling applications in understanding disease mechanisms, developing new treatments, and advancing biotechnology.